Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma
Clinical trial NCT03684694 · TERMINATED
Trial details
- NCT number
- NCT03684694
- Sponsor
- ADC Therapeutics S.A.
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-12-01
- Primary completion
- 2022-11-08
- Enrollment
- 136
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.